Clinical Trial Update: Aspirin in the Prevention of Cardiovascular Events in Hemodialysis Patients [Phase 4]

View source ↗

Summary

A Phase 4 trial studying aspirin for prevention of cardiovascular events in patients with end-stage renal disease undergoing hemodialysis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease

Drugs mentioned

• Aspirin (Aspirin)

Snippet

Sponsor: Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation | Conditions: End-Stage Renal Disease | Phase 4 | Status: WITHDRAWN